FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CANNON JAMES ANTHONY</u>						2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ZIOP]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 12/13/2006										Officer (give title Other (s below) below)				specify	
1285 AVENUE OF THE AMERICAS						If Amendment, Date of Original Filed (Month/Day/Year)									dividual or J	loint/Group	Filing	(Check Ap	plicable	
(Street) NEW YORK NY 10019					_										Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																				
		Tab	ole I - Non	-Deri	vativ	e Se	curitie	s Ac	quired,	Disp	osed o	f, or Be	enefi	cially	/ Owned					
Date					nsaction h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Inst				es Acquired (A) or Of (D) (Instr. 3, 4 and			s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)		rice	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock, \$.001 par value																0		D		
		-	Table II - I						uired, D s, option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution E if any (Month/Day	oate,	4. Transaction Code (Instr. 8)				6. Date Exercis. Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		xpiration vate	Title	Amo or Num of Sha	nber						
Director Stock Option (right to buy)	\$4.31								(1)	1	2/22/2014	Commor Stock, \$.001 par value	15	029		15,029	9	D		
Director Stock Option (right to buy)	\$5.01								04/26/200	6 0	4/26/2016	Commor Stock	15,	000		15,000	0	D		
Director Stock Option (right to buy)	\$6.49	12/13/2006			A		15,000		(2)	1	2/13/2016	Commor Stock	15,	000	\$0	15,000	0	D		

Explanation of Responses:

- 1.7,515 shares vest on 12/22/05 and 7,514 shares vest on 12/22/06.
- 2. 5,000 shares vest on each of 12/13/07, 12/13/08 and 12/13/09.

/s/ James A. Cannon

01/22/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.